^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    goserelin acetate

    i
    Other names: ZD-9393, ZD9393
    Company:
    Generic mfg.
    Drug class:
    GnRH agonist
    Related drugs:
    3d
    Multidimensional evaluation of different dosage forms of goserelin in the treatment of premenopausal HR+ breast cancer patients based on real-world data (ChiCTR2500112684)
    P=N/A, N=200, Recruiting, First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University
    New trial
    |
    PGR (Progesterone receptor)
    |
    goserelin acetate
    3d
    A randomized crossover trial on the preference of different preparations of goserelin for androgen deprivation therapy (ADT) in patients with prostate cancer (ChiCTR2500111711)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
    New trial
    |
    goserelin acetate
    3d
    A Multicenter Randomized Controlled Clinical Trial of Neoadjuvant Endocrine Therapy versus Chemotherapy in Patients with HR+/HER2- Early-Stage Breast Cancer (ChiCTR2500111780)
    P4, N=148, Not yet recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    paclitaxel • cyclophosphamide • Kisqali (ribociclib) • letrozole • epirubicin • goserelin acetate
    3d
    A Single-Arm Phase Ⅱ Clinical Study on the Ovarian Protective Effect of Goserelin Microspheres in Adjuvant Chemotherapy for Premenopausal Patients with Early-Stage Breast Cancer (ChiCTR2500112908)
    P2, N=25, Not yet recruiting, China-Japan Union Hospital of Jilin University; China-Japan Union Hospital of Jilin University
    New P2 trial
    |
    goserelin acetate
    3d
    A Phase II, Single-Arm Clinical Study of Goserelin Microspheres for Ovarian Function Preservation During Adjuvant Chemotherapy in Premenopausal Patients with Early Breast Cancer (ChiCTR2500113196)
    P2, N=25, Not yet recruiting, The Third Bethune Hospital of Jilin University; The Third Bethune Hospital of Jilin University
    New P2 trial
    |
    ER (Estrogen receptor)
    |
    ER negative
    |
    goserelin acetate
    11d
    NePtune: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (clinicaltrials.gov)
    P2, N=32, Recruiting, Rana McKay, MD | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L2 (RAD54 Like 2)
    |
    Lynparza (olaparib) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    12d
    Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Xiao X. Wei, MD | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • GEN1 (GEN1 Holliday junction 5' flap endonuclease)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    OncoPanel™ Assay
    |
    Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
    19d
    PreEMBER: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (clinicaltrials.gov)
    P2, N=600, Not yet recruiting, Eli Lilly and Company | Trial completion date: Jan 2029 --> Dec 2029
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    tamoxifen • Inluriyo (imlunestrant) • goserelin acetate
    20d
    APEX: Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    Xtandi (enzalutamide) • Eligard (leuprolide acetate) • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix)
    28d
    Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study. (PubMed, Breast)
    Sequential NET with palbociclib, limiting NAC to non-responders, is a feasible strategy for ER/PGR>50 %, HER2-, TP53 wild-type breast cancers.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53)
    |
    ER positive • TP53 wild-type
    |
    Ibrance (palbociclib) • tamoxifen • letrozole • goserelin acetate
    28d
    RWE About QOL and Compliance of Patients With OFS in China (clinicaltrials.gov)
    P=N/A, N=562, Completed, Fudan University | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Nov 2024 --> May 2025
    Trial completion date • Trial primary completion date • Real-world evidence • Compliance
    |
    goserelin acetate • leuprolide acetate for depot suspension
    1m
    Ribociclib plus endocrine therapy in bone marrow visceral crisis: challenging the chemotherapy paradigm in luminal metastatic breast cancer-a case report. (PubMed, Front Oncol)
    The patient was initially managed with letrozole and goserelin, followed by the addition of ribociclib. CDK4/6 inhibitors in combination with endocrine therapy may constitute an effective and well-tolerated alternative to chemotherapy in HR+/HER2- metastatic breast cancer presenting with visceral crisis, including hematologic compromise due to bone marrow involvement. This case underscores the need to reconsider current treatment algorithms to include targeted therapies as a viable and effective option in acute and life-threatening presentations of HR+/HER2- metastatic breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Kisqali (ribociclib) • letrozole • goserelin acetate